Illustration: Eniola Odetunde/Axios
Oncology and neuroscience biotech Eikon Therapeutics raised $381 million in its upsized IPO at $18 per share.
By the numbers: The offering values Eikon at about $908.2 million, based on outstanding shares, a decrease from its $1.85 billion valuation in 2025.
